T1	SNP 19 28	rs4442975
T2	Gene_Regulation 46 62	Binding Affinity
E1	Gene_Regulation:T2 Theme:T3 Agent:T1
T3	Entity 40 45	FOXA1
T4	Spec 63 66	Can
T5	Cell_types_tissues_affected 89 100	Suppression
E2	Cell_types_tissues_affected:T5 Theme:T30 Agent:T1
R1	Speculation_marker Arg1:E2 Arg2:T4	
T6	Entity 108 132	Neoadjuvant Chemotherapy
R2	Risk_Factor Arg1:T1 Arg2:T6	
T7	Association 67 76	Influence
E3	Association:T7 bc:T8 snp_int:T1
T8	Cancer 137 165	Luminal A Type Breast Cancer
A1	Cancer_Type T8 Horm+HER2-Ki67Low
T9	Entity 210 215	FOXA1
T11	Gene_Regulation 171 181	expression
E4	Gene_Regulation:T11 Theme:T9 Agent:T12
T12	SNP 323 332	rs4442975
T13	Spec 333 336	can
T14	Organic_inorganic_molecules_affected 350 358	function
E5	Organic_inorganic_molecules_affected:T14 Agent:T12 Theme:T15
R5	Speculation_marker Arg1:E5 Arg2:T13	
T15	Entity 344 349	FOXA1
T16	Association 239 248	prognosis
E6	Association:T16 bc:T17 snp_int:T12
T17	Cancer 252 269;275 297	estrogen receptor positive breast cancer
T18	Entity 271 273	ER
T19	Entity 252 269	estrogen receptor
R6	Equiv Arg1:T18 Arg2:T19	
T20	Effect_Type 275 283	positive
T21	Organic_inorganic_molecules_affected 219 229	associated
E7	Organic_inorganic_molecules_affected:T21 Theme:T19 Agent:T12
R7	Effect_type_marker Arg1:E7 Arg2:T20	
A2	Effect_Type E7 Increase
T22	Therapeutic_response 429 437	efficacy
E8	Therapeutic_response:T22 Agent:T24
T23	Entity 441 465	neoadjuvant chemotherapy
T24	SNP 411 420	rs4442975
T25	Spec 374 386	investigated
R8	Speculation_marker Arg1:E8 Arg2:T25	
T26	Cancer 470 498	luminal A type breast cancer
A3	Cancer_Type T26 Horm+HER2-Ki67Low
T27	Entity 541 559	Chinese population
R9	Population_assignment Arg1:T24 Arg2:T27	
T28	Entity 639 663	neoadjuvant chemotherapy
T29	Association 466 469	for
E9	Association:T29 snp_int:T24 bc:T26
T30	Entity 77 88	Bone Marrow
T31	Entity 695 705	epirubicin
T32	Entity 710 719	docetaxel
R10	Member Arg1:T28 Arg2:T31	
R11	Member Arg1:T28 Arg2:T32	
T33	Therapeutic_response 517 535	toxic side effects
E10	Therapeutic_response:T33 Agent:T24
T34	Spec 503 512	evaluated
R12	Speculation_marker Arg1:E10 Arg2:T34	
T35	Spec 905 912	analyze
T36	Therapeutic_response 953 961	efficacy
E11	Therapeutic_response:T36 Agent:T39
T37	Therapeutic_response 966 978	side effects
E12	Therapeutic_response:T37 Agent:T39
T38	Entity 982 1006	neoadjuvant chemotherapy
R13	Speculation_marker Arg1:E11 Arg2:T35	
T39	SNP 932 943	the variant
R14	Equiv Arg1:T39 Arg2:T24	
T40	Effect_Type 1039 1047	positive
T41	Therapeutic_response 1069 1077	efficacy
E13	Therapeutic_response:T41 Agent:T45
R15	Negation_marker Arg1:E13 Arg2:T10	
T43	Therapeutic_response 1225 1243	toxic side effects
E14	Therapeutic_response:T43 Agent:T45
T44	Entity 1247 1271	neoadjuvant chemotherapy
T45	SNP 1284 1293	rs4442975
T46	Entity 1314 1325	bone marrow
T47	Cell_types_tissues_affected 1326 1337	suppression
E15	Cell_types_tissues_affected:T47 Theme:T46 Agent:T45
R16	Risk_Factor Arg1:T45 Arg2:T44	
R17	Equiv Arg1:E15 Arg2:E14	
T48	SNP 1473 1482	rs4442975
T49	Cell_types_tissues_affected 1515 1526	suppression
E16	Cell_types_tissues_affected:T49 Agent:T48 Theme:T51
T50	Entity 1534 1558	neoadjuvant chemotherapy
R18	Risk_Factor Arg1:T48 Arg2:T50	
T51	Entity 1503 1514	bone marrow
T52	Cancer 1563 1591	luminal A type breast cancer
A4	Cancer_Type T52 Horm+HER2-Ki67Low
T53	Association 1559 1562	for
E17	Association:T53 bc:T52 snp_int:T48
A5	Cancer_Type T17 ER+
R21	Risk_Factor Arg1:T24 Arg2:T23	
R22	Equiv Arg1:T28 Arg2:T23	
R23	Risk_Factor Arg1:T39 Arg2:T38	
R4	Equiv Arg1:T28 Arg2:T38	
R24	Risk_Factor Arg1:T39 Arg2:T38	
T10	Neg 1035 1038	any
R19	Effect_type_marker Arg1:E13 Arg2:T40	
A6	Effect_Type E13 Increase
T42	Effect_Type 1326 1337	suppression
A7	Effect_Type E15 Decrease
R20	Effect_type_marker Arg1:E15 Arg2:T42	
R25	Equiv Arg1:T44 Arg2:T28	
R3	Equiv Arg1:T6 Arg2:T23	
T54	Effect_Type 1515 1526	suppression
R26	Effect_type_marker Arg1:E16 Arg2:T54	
A8	Effect_Type E16 Decrease
